Clinical Diagnosis

Marguerite B. McDonald, MD, FACS, shares a front-row view of ophthalmology’s “revolution with a capital R."

The ADAPT study will evaluate the safety and effectiveness of the Calibreye surgical system in up to 70 patients with refractory glaucoma.

Hidden signs of systemic disease, including heart attacks, may first reveal themselves through visual symptoms or subtle patient cues in the exam chair.

Current applications and future outlook on integrating robotic technology in the operating room.

Real-time data analysis and intelligent automation help streamline key steps.

Robotic laser arcuate incisions reduce variability and residual astigmatism.

The Eye Care Network connected with Haller to hear her vision for Wills Eye Hospital, her priorities as CEO, and what lies ahead for the field of ophthalmology.

At the CCOI-Stanford Summit, Goldberg calls for collaborative trial models that could redefine efficiency and standardization in ophthalmology research.

At the 2025 International SPECTRALIS Symposium—And Beyond (ISS), Chauhan discussed how two-photon microscopy enables precise, non-invasive monitoring of retinal ganglion cell function in living subjects.

A new study demonstrates that handheld nanopore sequencers can rapidly identify eye infection pathogens using only a patient’s tears.

From Nobel laureates to AI-driven research, the Wilmer Eye Institute honors a century of transforming vision science and care.

Ixo-vec shows sustained efficacy and reduces injection burden through 4 years in clinical trials

As its director, Manusis outlines the facility’s role in delivering advanced, personalized solutions to improve vision and patient experience.

Changing demographics and increasing trial complexity present challenges and opportunities.

From laser vision correction to adjustable lens implants, the Center for Refractive Solutions at New York Eye and Ear Infirmary of Mount Sinai offers advanced options for every stage of life.

A look at current therapies, clinical trial results, patient education, and emerging options for managing this progressive retinal disease.

With detailed imaging and cognitive data, the Northern Ireland Cohort for the Longitudinal Study of Aging highlights the potential of integrating eye scans into broader health research.

Optical coherence tomography markers—like the ellipsoid zone—are reshaping clinical trials in intermediate age-related macular degeneration, as highlighted at the 2025 International SPECTRALIS Symposium — And Beyond (ISS).

Advanced monitoring strategies are overcoming significant obstacles in retinal care, as highlighted at the 2025 International SPECTRALIS Symposium — And Beyond (ISS).

Fluorescence lifetime imaging ophthalmoscopy is emerging as a valuable tool to reveal previously hidden links between retinal changes and systemic disease.

The center aims to optimize patients' vision with a range of cataract and corneal refractive procedures and minimize reliance on glasses and contacts.

NASA’s development of autonomous eye imaging technologies for astronauts aboard the International Space Station is paving the way for remote, high-quality eye care both in deep space and underserved regions on Earth.

Advanced autofluorescence reveals cellular pigment reservoirs with therapeutic potential at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

This noninvasive imaging tool reveals early brain pathology through the eye, promising faster and more accurate diagnoses as highlighted at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

Findings presented at the Heidelberg 2025 International SPECTRALIS Symposium — And Beyond (ISS) suggest detailed structural data could better inform therapeutic targeting and monitoring.

Improved axial resolution allows clearer visualization of early atrophic changes, including iRORA vs cRORA differentiation, as shared at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

From basal laminar deposits to foveal centering, a new framework refines what clinicians see—and what they treat—in outer retinal disease, as presented at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

With 35+ lectures, a NASA keynote, and a river cruise through historic Heidelberg, this year’s symposium blends science and scenery

On the heels of the drug's FDA approval, clinicians weigh in on acoltremon’s (Tryptyr) novel mechanism of action and its potential to address unmet needs in dry eye care